Tags

Type your tag names separated by a space and hit enter

Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Rev Med Virol. 2020 09; 30(5):e2136.RM

Abstract

SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections.

Authors+Show Affiliations

Department of Family Medicine, Regional Medical Center of Central Alabama, Greenville, Alabama, USA.Department of OB/GYN, Valley Community Healthcare, North Hollywood, California, USA.Department of Family Medicine, University of Alabama, Tuscaloosa, Alabama, USA.Garden OB/GYN, Mercy Medical Center, New York, New York, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32644275

Citation

Giovane, Richard A., et al. "Current Pharmacological Modalities for Management of Novel Coronavirus Disease 2019 (COVID-19) and the Rationale for Their Utilization: a Review." Reviews in Medical Virology, vol. 30, no. 5, 2020, pp. e2136.
Giovane RA, Rezai S, Cleland E, et al. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Rev Med Virol. 2020;30(5):e2136.
Giovane, R. A., Rezai, S., Cleland, E., & Henderson, C. E. (2020). Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. Reviews in Medical Virology, 30(5), e2136. https://doi.org/10.1002/rmv.2136
Giovane RA, et al. Current Pharmacological Modalities for Management of Novel Coronavirus Disease 2019 (COVID-19) and the Rationale for Their Utilization: a Review. Rev Med Virol. 2020;30(5):e2136. PubMed PMID: 32644275.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review. AU - Giovane,Richard A, AU - Rezai,Shadi, AU - Cleland,Ellen, AU - Henderson,Cassandra E, Y1 - 2020/07/09/ PY - 2020/04/30/received PY - 2020/06/01/revised PY - 2020/06/02/accepted PY - 2020/7/10/pubmed PY - 2020/10/2/medline PY - 2020/7/10/entrez KW - 2019-nCoV KW - COVID-19 KW - Lopinavir/Ritonavir KW - RNA-dependent RNA polymerase inhibitors KW - Remdesivir KW - SARS CoV-2 KW - SARS coronavirus (SARS-CoV) KW - Umifenovir KW - acetazolamide KW - acute respiratory distress syndrome (ARDS) KW - autoimmune KW - camostat mesylate KW - chloroquine KW - high altitude pulmonary edema (HAPE) KW - hydroxychloroquine KW - novel coronavirus 2019 KW - pandemic KW - severe acute respiratory syndrome (SARS) SP - e2136 EP - e2136 JF - Reviews in medical virology JO - Rev Med Virol VL - 30 IS - 5 N2 - SARS-CoV-2 has caused a pandemic which is putting strain on the health-care system and global economy. There is much pressure to develop both preventative and curative therapies for SARS-CoV-2 as there is no evidence to support therapies to improve outcomes in patients with SARS-CoV-2. Medications that inhibit certain steps of virus life cycle that are currently used to treat other illnesses such as Malaria, Ebola, HIV and Hepatitis C are being studied for use against SARS-CoV-2. To date, data is limited for medications that facilitate clinical improvement of COVID-19 infections. SN - 1099-1654 UR - https://www.unboundmedicine.com/medline/citation/32644275/Current_pharmacological_modalities_for_management_of_novel_coronavirus_disease_2019__COVID_19__and_the_rationale_for_their_utilization:_A_review_ L2 - https://doi.org/10.1002/rmv.2136 DB - PRIME DP - Unbound Medicine ER -